Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial

BACKGROUND: Preclinical investigations support combining sorafenib with IL-2 in the treatment of metastatic renal cell carcinoma (mRCC). METHODS: In this open-label, phase II study, 128 patients with mRCC were randomised to receive oral sorafenib, 400 mg twice daily, plus subcutaneous IL-2, 4.5 mill...

Descripción completa

Detalles Bibliográficos
Autores principales: Procopio, G, Verzoni, E, Bracarda, S, Ricci, S, Sacco, C, Ridolfi, L, Porta, C, Miceli, R, Zilembo, N, Bajetta, E
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3078589/
https://www.ncbi.nlm.nih.gov/pubmed/21448165
http://dx.doi.org/10.1038/bjc.2011.103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3078589/
https://www.ncbi.nlm.nih.gov/pubmed/21448165
http://dx.doi.org/10.1038/bjc.2011.103

Ejemplares similares